Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ra Capital Management, L.P. Sells 128,770 Shares

by · The Markets Daily

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ra Capital Management, L.P. sold 128,770 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $0.39, for a total transaction of $50,220.30. Following the completion of the sale, the insider owned 341,353 shares of the company’s stock, valued at $133,127.67. This trade represents a 27.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

  • On Tuesday, June 16th, Ra Capital Management, L.P. sold 149,625 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $55,361.25.
  • On Friday, June 12th, Ra Capital Management, L.P. sold 170,441 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total transaction of $68,176.40.
  • On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total transaction of $99,751.14.
  • On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $16,991.51.
  • On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $136,826.00.
  • On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $64,736.64.
  • On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $58,618.30.
  • On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Trading Down 7.4%

Shares of HOWL traded down $0.03 during mid-day trading on Tuesday, hitting $0.36. The company’s stock had a trading volume of 580,233 shares, compared to its average volume of 468,701. The company’s 50-day moving average is $0.65 and its 200-day moving average is $0.71. Werewolf Therapeutics, Inc. has a 52-week low of $0.36 and a 52-week high of $2.38. The firm has a market capitalization of $17.50 million, a price-to-earnings ratio of -0.29 and a beta of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on HOWL. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $3.75.

Check Out Our Latest Stock Report on HOWL

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. AQR Capital Management LLC purchased a new stake in Werewolf Therapeutics in the 1st quarter worth $79,000. Marshall Wace LLP purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth $113,000. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth $48,000. Jane Street Group LLC purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth $409,000. Finally, Bank of America Corp DE increased its holdings in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.

Read More